Quality of life outcomes from a dose-per-fraction escalation trial of hypofractionation in prostate cancer.

ABSTRACT:

Objective

This multi-institutional phase I/II trial explored patient-assessed tolerance of increasingly hypofractionated (HPFX) radiation for low/intermediate risk prostate cancer.

Methods

347 patients enrolled from 2002 to 2010. Three increasing dose-per-fraction schedules of 64.7 Gy/22 fx, 58.08 Gy/16 fx and 51.6 Gy/12 fx were each designed to yield equivalent predicted late toxicity. Three quality of life (QoL) surveys were administered prior to treatment and annually upto 3 years.

Results

Bowel QoL data at 3years revealed no significant difference among regimens (p=0.469). Bowel QoL for all regimens declined transiently, largely recovering by three years, with only the 22 fraction decrement reaching significance. Bladder outcomes at 3 years were comparable (p=0.34

SUBMITTER: Brower JV 

PROVIDER: S-EPMC4764419 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature